Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables

BMC Public Health

Table 3 Patient characteristics by duration of diabetes

Diabetes duration (yrs)	n (%)^a	Mean±SD HbA1c (%)	Concomitant disease/ complication (%)^b	Achieved HbA1c <7.0% (%)^b	OAD (%)^b	Insulin + OAD (%)^b	GLP-1 RA + OAD (%)^b
<1	36,337 (15.22)	8.12±1.99	12,663 (34.85)	11,007 (30.29)	26,372 (72.58)	9909 (27.27)	56 (0.15)
≥1-5	102,550 (42.97)	7.66±1.61	45,533 (44.40)	36,331 (35.43)	75,459 (73.58)	26,896 (26.23)	195 (0.19)
≥5-10	55,744 (23.36)	7.84±1.66	34,374 (61.67)	16,915 (30.34)	34,446 (61.79)	21,159 (37.96)	139 (0.25)
≥10	44,003 (18.44)	8.09±1.76	31,607 (71.83)	11,575 (26.31)	20,933 (47.57)	23,006 (52.28)	64 (0.15)
P value^c		<0.0001	<0.0001	<0.0001	<0.0001	NS	NS

^aPercentage of patients among the full population; ^bPercentage of patients among the patients with particular diabetes duration; ^cANOVA and chi-square test were used as appropriate.
GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated hemoglobin; NS = not significant; OAD, oral antidiabetes drug; SD, standard deviation.

ISSN: 1471-2458